Hester Biosciences FY21 Annual Report Takeaways ๐
'Hester is the only Company in ๐ฎ๐ณ that has a Lumpy Skin Disease (LSD) vaccine under development.'
Hit the 'retweet' & help us educate more investors.
A Thread ๐งต๐
'Hester is the only Company in ๐ฎ๐ณ that has a Lumpy Skin Disease (LSD) vaccine under development.'
Hit the 'retweet' & help us educate more investors.
A Thread ๐งต๐
1/ About the company
One of the fastest-growing poultry & animal healthcare companies globally (10yr sales growth: of 18%)
Widening portfolio through R&D investments
Have been investments aggressively in capacity augmentation (gross block cagr of 16% from FY16-21)
One of the fastest-growing poultry & animal healthcare companies globally (10yr sales growth: of 18%)
Widening portfolio through R&D investments
Have been investments aggressively in capacity augmentation (gross block cagr of 16% from FY16-21)
2/ Numbers that matter
Rev up 23%
35% EBITDA margin
Pat up 28%
Strong cashflows
Consol Debt of about 100crs
2nd largest poultry vaccine manufacturer in ๐ฎ๐ณ
Present in 30+ countries
899 Cr doses annual capacity
Rev up 23%
35% EBITDA margin
Pat up 28%
Strong cashflows
Consol Debt of about 100crs
2nd largest poultry vaccine manufacturer in ๐ฎ๐ณ
Present in 30+ countries
899 Cr doses annual capacity
3/ Innovation
- New category of herbal products for poultry & animals
- First vaccine to be launched for Lumpy skin disease in ๐ฎ๐ณ
The total set of products:
Poultry- 18 live & 30 inactivated vaccines
Animal- 3 live vaccines
- New category of herbal products for poultry & animals
- First vaccine to be launched for Lumpy skin disease in ๐ฎ๐ณ
The total set of products:
Poultry- 18 live & 30 inactivated vaccines
Animal- 3 live vaccines
4/ Business updates
- One of Africa's largest vaccine capacities going online by Dec 2021: Spent 100+ crs
- Launched 13 new herbal products for poultry, cattle, ๐, ๐& swine
- Increased transmissibility of diseases from animals to humans: Govts spending more on animal vaccines
- One of Africa's largest vaccine capacities going online by Dec 2021: Spent 100+ crs
- Launched 13 new herbal products for poultry, cattle, ๐, ๐& swine
- Increased transmissibility of diseases from animals to humans: Govts spending more on animal vaccines
5/ Subsidiaries, manufacturing & distribution capability
- Ability for last-mile delivery in ๐ฎ๐ณ,๐ณ๐ต(Nepal) &๐ (Africa)
- Economies of scale: Asiaโs largest single-location animal biological manufacturing facility
- Products complying with WHO, GMP, GLP & ISO 9001:2015 standards
- Ability for last-mile delivery in ๐ฎ๐ณ,๐ณ๐ต(Nepal) &๐ (Africa)
- Economies of scale: Asiaโs largest single-location animal biological manufacturing facility
- Products complying with WHO, GMP, GLP & ISO 9001:2015 standards
6/ From the desk of the CEO (Mr. Rajiv)
- Business: Poultry (up 25%) outperformed Animal (up 19%) & India (up 29%) outperformed exports (down 4% due to supply chain issues)
- Incremental R&D going in large animals & developing the drug substance for Bharat Biotech's COVAXIN
- Business: Poultry (up 25%) outperformed Animal (up 19%) & India (up 29%) outperformed exports (down 4% due to supply chain issues)
- Incremental R&D going in large animals & developing the drug substance for Bharat Biotech's COVAXIN
7/ The global & the Indian Animal Healthcare business
- Driven by protein demand, increased incidence of Zootonic & food-borne diseases, adoption of pet health insurance in the west
- Potential for India (domestic market: $1B+) to become an export hub for APIs & formulations
- Driven by protein demand, increased incidence of Zootonic & food-borne diseases, adoption of pet health insurance in the west
- Potential for India (domestic market: $1B+) to become an export hub for APIs & formulations
8/ Outlook for the business
- Has plans to get into newer territories & with newer products in the pipeline: broaden the breadth & depth of the supply chain
- Technological collaborations with the govt & other private institutions
- Looking to monopolize in few vaccines.
- Has plans to get into newer territories & with newer products in the pipeline: broaden the breadth & depth of the supply chain
- Technological collaborations with the govt & other private institutions
- Looking to monopolize in few vaccines.
9/ Risks & how they plan to mitigate it.
A company with the potential to scale multifold as new capacities come up (implementation risks) with a promoter who has a fire in the belly.
Nevertheless, Need to track the numerous risks this business entails.
End of Thread.
A company with the potential to scale multifold as new capacities come up (implementation risks) with a promoter who has a fire in the belly.
Nevertheless, Need to track the numerous risks this business entails.
End of Thread.
Here's a glossary for all the complex abbreviations mentioned above ๐
Ask us any questions that arise about Hester's business in the comments section.
Ask us any questions that arise about Hester's business in the comments section.
Hester Bioscienceโs Q4FY21 results coverage ๐
Loading suggestions...